title: Regulatory T Cell Immunotherapy for Type 1 Diabetes: A Step Closer to Success?
abstract: Regulatory T cell (Treg) therapy has shown promises in experimental models of type 1 diabetes (T1D) and other autoimmune diseases. Now, Bluestone et al. (2015) report in a phase 1, dose-escalation study that ex vivo-expanded autologous polyclonal Treg therapy is safe and well tolerated in adult patients with recent-onset T1D.
authors: Institut National de la Santé et de la Recherche Médicale Unité 1138, Paris 75006, France; Sorbonne Universités, UPMC Univ Paris 06, UMR S 1138, Paris 75006, France; Université Paris Descartes, Sorbonne Paris Cité, UMR S 1138, Paris 75006, France; Centre de Recherche des Cordeliers, Equipe - Immunopathologie et immuno-intervention thérapeutique, Paris 75006, France. Electronic address: jagadeesh.bayry@crc.jussieu.fr.
authors: Jagadeesh
authors: J
authors: Bayry
authors: Institut National de la Santé et de la Recherche Médicale Unité 1138, Paris 75006, France; Sorbonne Universités, UPMC Univ Paris 06, UMR S 1138, Paris 75006, France; Université Paris Descartes, Sorbonne Paris Cité, UMR S 1138, Paris 75006, France; Centre de Recherche des Cordeliers, Equipe - Pathogenèse cellulaire et clinique du diabète, Paris 75006, France; Service de Diabétologie, Endocrinologie, Nutrition, Centre Universitaire du Diabète et de ses Complications, Hôpital Lariboisière, University Paris-Diderot Paris-7, Paris 75010, France.
authors: Jean-François
authors: JF
authors: Gautier
mesh_terms: D003922:Diabetes Mellitus, Type 1 / Q000378:metabolism*; D006801:Humans; D007167:Immunotherapy; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*